TITLE

LONG-TERM SOLIRIS TREATMENT IMPROVES KIDNEY FUNCTION

PUB. DATE
January 2010
SOURCE
Biotech Business;Jan2010, Vol. 23 Issue 1, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the findings of Alexion Pharmaceuticals, Inc. from its 26-week extension of the AEGIS study, an open-label registration study focused on showing Soliris as treatment for Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). It affirmed that patients with chronic kidney disease (CKD) either stabilized or improved after taking the medicine. A comment from Dr. Yuzuru Kanakura of Osaka University Hospital is presented.
ACCESSION #
47191336

 

Related Articles

  • American Society of Hematology 2007.  // BioWorld Today;12/11/2007, Vol. 18 Issue 239, p3 

    The article reports on the open-label clinical study conducted by Alexion Pharmaceuticals Inc. According to the Cheshire, Connecticut-based company, paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder, was more likely for the general public to have than chronic kidney disease....

  • Alexion Defies Biotech's Slow Sales Trend; Beats Estimates.  // Bioworld Week;7/25/2011, Vol. 19 Issue 30, p5 

    The article reports on the slow sales trend of drug Soliris (eculizumab) manufactured by Alexion Pharmaceuticals Inc. of Cheshire, Connecticut for the treatment of paroxysmal nocturnal hemoglobinuria.

  • Alexion Pharmaceuticals. Investor's Business Daily // Investors Business Daily;4/13/2015, pA02 

    The article focuses on the approval given to Alexion Pharmaceuticals Inc. (ALXN) which will allow update of the label of its drug Soliris for paroxysmal nocturnal hemoglobinuria to include patients without history of transfusion.

  • ALEXION ENROLLS ECULIZUMAB PHASE III SHEPHERD TRIAL.  // Biotech Business;Nov2006, Vol. 19 Issue 11, p1 

    The article reports on the completion of the phase III shepherd trial of eculizumab by Alexion Pharmaceuticals, Inc. in Cheshire, Connecticut. It offers information on monoclonal antibody eculizumab, shepherd trial and paroxysmal nocturnal hemoglobinuria (PNH). The trial was conducted in...

  • EARNINGS ROUNDUP.  // BioWorld Today;10/27/2008, Vol. 19 Issue 209, p3 

    The article reports that Alexion Pharmaceuticals Inc. of Cheshire, Connecticut reported total revenue of $76.5 million for the third quarter of 2008. According to the article, this came from sales of paroxysmal nocturnal hemoglobinuria drug Soliris which were up from the $21.8 milion in revenues...

  • Alexion Reports 3rd Qtr 2011 Results.  // Biomedical Market Newsletter;10/26/2011, Vol. 21, p841 

    The article reports on the announcement of Alexion Pharmaceuticals Inc. for its financial results for the 3 and 9 months that ended September 30, 2011 in Cheshire, Connecticut. The company has reported 204.0 million U.S. dollar total revenues in the third quarter of 2010 from net product sales...

  • CHMP ADOPTS POSITIVE OPINION FOR ALEXION'S SOLIRIS IN EUROPE.  // Worldwide Biotech;Jun2007, Vol. 19 Issue 6, p5 

    The article reports that the Committee for Human Medicinal Products of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for Soliris, a drug from Alexion Pharmaceuticals Inc. The drug is for patients with paroxysmal nocturnal hemoglobinuria (PNH)....

  • New biologic: Soliris.  // Formulary;Apr2007, Vol. 42 Issue 4, p215 

    The article reports on the approval of recombinant monoclonal antibody eculizumab from Alexion Pharmaceuticals Inc. for the treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis. Its efficacy is evaluated in a randomized placebo-controlled 26-week study, and a single-arm 52-week...

  • Alexion Soars On Earnings Report.  // BioWorld Today;7/26/2007, Vol. 18 Issue 144, p3 

    The article reveals the increase in the shares of Cheshire, Connecticut-based Alexion Pharmaceuticals Inc. after it released its second-quarter earnings, which showed a smaller than predicted loss. Alexion reported total revenues of $9.8 million, all from sales of recently launched Soliris, and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics